The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataReduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.The effect of grapefruit juice on drug disposition.Cytochrome P450 2C8 pharmacogenetics: a review of clinical studiesThe effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Grapefruit-drug interactions: can interactions with drugs be avoided?CYP2C8 and antimalaria drug efficacy.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Pharmacogenomics of glinides.Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanismDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
P2860
Q27009128-D7686A5A-1317-49BC-A9F8-7046C97284A6Q30776360-F805A451-8AE4-4C76-88DD-5ED15A5A8CE9Q34764136-ABC0E38B-56AA-4784-BA23-4ABBB64CBCD9Q35003605-C92F34D4-75E6-496A-8BB4-0B67AB817015Q35827919-B4B592E6-EA8D-48AF-994D-C9E16C547F5AQ36652594-1A6181DC-AD43-4D74-A5D8-0747AC660240Q36730638-BCFA7C82-E744-4F81-A597-FFDE69C6CEA9Q37960129-574B515B-6F26-4FA8-92DE-013E9488D630Q38059889-216E16FC-6EA1-4F99-B0C7-7AE0D1D3B3E8Q38110432-2C97411E-A410-4F41-B24A-2419D6C2B044Q38130410-9A95C770-92C7-4680-80DB-CC7DCFE6CDE4Q38307994-98129218-3EFD-4005-AA90-AD90708EAB65Q38365410-DACD9A1D-F103-4AEF-A504-85B38B3CFE76Q38437256-A2F0D496-9FDF-4318-91E2-C563A6E7BCA9Q38684505-A78DA5B9-8B19-4F37-91B9-54937BD0E832Q38928302-31919B0C-BB7F-486E-943B-21A7A759DE64Q41589503-8DC106B1-8C82-48D4-A0A4-510EE3D1D393Q46813708-07919833-D186-4627-BB49-024C8CB70510
P2860
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@ast
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@en
type
label
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@ast
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@en
prefLabel
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@ast
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@en
P2093
P2860
P1476
The impact of CYP2C8 polymorph ...... armacokinetics of repaglinide.
@en
P2093
Anders Karlsson
Anette Kristensen Olsen
Marianne Ekblom
Tanja Busk Bidstrup
P2860
P356
10.1111/J.1365-2125.2005.02516.X
P407
P577
2006-01-01T00:00:00Z